

Preferences and Acceptability for Long-Acting PrEP Agents Among Pregnant and Postpartum Women with Experience Using Daily Oral PrEP in South Africa and Kenya

Authors: Nafisa J. Wara^{1§}, Rufaro Mvududu², Mary M. Marwa³, Laurén Gómez⁴, Nyiko Mashele², Catherine Orrell⁵, Corrina Moucheraud⁶, John Kinuthia^{3,4}, Grace John-Stewart^{4,7,8,9}, Landon Myer², Risa Hoffman¹⁰, Jillian Pintye^{4,11}, Dvora L. Joseph Davey^{2,10,12}

Affiliations:

¹David Geffen School of Medicine at the University of California, Los Angeles, Los Angeles, California, USA

²Division of Epidemiology and Biostatistics, School of Public Health, University of Cape Town, Cape Town, South Africa

³Department of Research and Programs, Kenyatta National Hospital, Nairobi, Kenya

⁴Department of Global Health, University of Washington, Seattle, Washington, USA

⁵Desmond Tutu HIV Centre, Institute of Infectious Disease and Molecular Medicine and the Department of Medicine, University of Cape Town, South Africa

⁶Department of Health Policy and Management, Fielding School of Public Health, University of California Los Angeles, Los Angeles, California, USA

⁷Department of Epidemiology, University of Washington, Seattle, Washington, USA

⁸Department of Medicine, University of Washington, Seattle, Washington, USA

⁹Department of Pediatrics, University of Washington, Seattle, Washington, USA

¹⁰Division of Infectious Diseases, David Geffen School of Medicine at the University of California, Los Angeles, Los Angeles, California, USA

¹¹Department of Biobehavioral Nursing and Health Informatics, University of Washington, Seattle, Washington, USA

¹²Department of Epidemiology, Fielding School of Public Health, University of California Los Angeles, Los Angeles, California, USA

Correspondence:

Nafisa Wara

Email: nwara@mednet.ucla.edu

Telephone: 518-577-3170

Address: 10833 Le Conte Ave, Los Angeles CA 90095

Keywords: PrEP, long-acting, pregnancy, breastfeeding, South Africa, Kenya

Email addresses of authors:

NJW: nwara@mednet.ucla.edu

RM: rufaro.mvududu@uct.ac.za

MMM: mmarwa@uw.edu

LG: gomezl4@uw.edu

NM: nyiko.mashele@uct.ac.za

CO: Catherine.orrell@hiv-research.org.za

CM: cmoucheraud@g.ucla.edu

JK: kinuthia@uw.edu

GJ-S: gjohn@uw.edu

LM: landon.myer@uct.ac.za

RH: rhoffman@mednet.ucla.edu

JP: jpintye@uw.edu

DLJD: dvora.josephdavey@uct.ac.za

1 **Abstract**

2

3 **Introduction:** Long-acting pre-exposure prophylaxis (PrEP) options could overcome some barriers to oral
4 PrEP persistence during pregnancy and postpartum. We evaluated long-acting PrEP preferences among
5 oral PrEP-experienced pregnant and postpartum women in South Africa and Kenya, two countries with
6 high coverage of oral PrEP and with pending regulatory approvals for long-acting injectable cabotegravir
7 and the dapivirine vaginal ring (approved in South Africa, under review in Kenya).

8

9 **Methods:** From September 2021 to February 2022, we surveyed pregnant and postpartum women
10 enrolled in oral PrEP studies in South Africa and Kenya. We evaluated oral PrEP attitudes and preferences
11 for existing and future long-acting PrEP methods.

12

13 **Results:** We surveyed 190 women in South Africa (67% postpartum; median age 27 years [IQR 22-32]) and
14 204 women in Kenya (79% postpartum; median age 29 years [IQR 25-33]). 75% of participants reported
15 oral PrEP use within the last 30 days. Overall, 49% of participants reported negative oral PrEP attributes,
16 including side effects (21% South Africa, 30% Kenya) and pill burden (20% South Africa, 25% Kenya).
17 Preferred PrEP attributes included long-acting method, effectiveness, safety while pregnant and
18 breastfeeding, and free medication. Most participants (75%, South Africa and Kenya) preferred a potential
19 long-acting injectable over oral PrEP, most frequently for longer duration of effectiveness in South Africa
20 (87% South Africa, 42% Kenya) versus discretion in Kenya (5% South Africa, 49% Kenya). 87% of participants
21 preferred oral PrEP over a potential long-acting vaginal ring, mostly due to concern about possible
22 discomfort with vaginal insertion (82% South Africa, 48% Kenya). Significant predictors of long-acting PrEP
23 preference included past use of injectable contraceptive (aOR 2.48, 95% CI: 1.34, 4.57), disliking at least
24 one oral PrEP attribute (aOR 1.72, 95% CI: 1.05, 2.80), and preferring infrequent PrEP use (aOR 1.58, 95%
25 CI: 0.94, 2.65).

26

27 **Conclusions:** Oral PrEP-experienced pregnant and postpartum women expressed a theoretical preference
28 for long-acting injectable PrEP over other modalities, demonstrating potential acceptability among a key
29 population who must be at the forefront of injectable PrEP rollout. Reasons for PrEP preferences differed
30 by country, emphasizing the importance of increasing context-specific options and choice of PrEP
31 modalities for pregnant and postpartum women.

32 Introduction

33 HIV incidence remains high among cisgender women of reproductive age in South Africa and Kenya,
34 including during pregnancy and postpartum[1-4]. Pregnant women without HIV are at elevated risk of
35 acquisition due to structural and sociocultural factors (e.g., poverty, gender inequity) that may result in
36 high-risk scenarios, including not knowing the HIV status of their partner(s), engaging in sexual activity
37 without condoms, and having multiple sex partners[5-8]. Furthermore, the risk of vertical HIV transmission
38 is elevated during pregnancy and breastfeeding due to acute maternal HIV infection[9,10]. A concerted
39 effort is needed to reduce HIV infections among pregnant and breastfeeding individuals, and their infants.

40 Daily oral tenofovir disoproxil fumarate/emtricitabine (TDF/FTC) pre-exposure prophylaxis (PrEP) for HIV
41 prevention is being rapidly scaled in South Africa and Kenya, and these two countries have the highest and
42 second highest number of PrEP initiations globally[11]. Studies have reported high rates of oral PrEP
43 uptake among pregnant and postpartum women in South Africa and Kenya[12,13]. However, the delivery
44 of daily oral PrEP among pregnant and postpartum women is challenged by insufficient integration of PrEP
45 provision and counseling into existing antenatal and postpartum systems[14]. Furthermore, self-reported
46 adherence on oral PrEP (e.g., taking PrEP daily) was low among pregnant and postpartum women in Kenya,
47 and limited adherence was identified among pregnant and postpartum women taking oral PrEP in South
48 Africa through dried blood spot analysis[13,15]. Substantial barriers to oral PrEP adherence exist in these
49 populations, including pill burden, stigma and limited disclosure of PrEP use, and financial and logistical
50 barriers to accessing a clinic for PrEP[16-18]. Strategies to overcome barriers to PrEP adherence are
51 urgently needed.

52 Long-acting modalities, such as injectable cabotegravir (CAB-LA) and the dapivirine vaginal ring, may
53 improve PrEP initiation and persistence among pregnant and postpartum women. CAB-LA, an
54 intramuscular injection administered every eight weeks, is superior to oral PrEP, reducing risk of HIV
55 infection by 88% compared to daily oral TDF/FTC among cisgender women in Sub-Saharan Africa[19].
56 Preliminary data show that CAB-LA is well tolerated during pregnancy and has a similar pharmacokinetic
57 profile to its use by nonpregnant women[20,21]. CAB-LA received regulatory approval in the United States
58 in December 2021 and is pending regulatory approval in South Africa, Kenya, and other countries in
59 Southern Africa[11]. The dapivirine ring, inserted vaginally and replaced every four weeks, has been shown
60 to reduce the risk of HIV infection by approximately 30% and is not associated with adverse pregnancy or
61 infant outcomes[22]. The dapivirine ring received regulatory approval in South Africa in March 2022, and is
62 pending approval in Kenya[11]. These developments highlight the urgent need to understand potential
63 facilitators and barriers to uptake and persistence on these novel PrEP methods among pregnant and

64 postpartum women. Our study aims to assess preferences for and perceptions of long-acting PrEP methods
65 among oral PrEP-experienced pregnant and postpartum women in Kenya and South Africa.

66

67 **Methods**

68 **Study participants:** We conducted surveys with participants enrolled in an observational cohort study
69 assessing daily oral PrEP initiation and persistence among pregnant and breastfeeding women (PBFW) in
70 Cape Town, South Africa (PrEP-PP) and an observational extension cohort of a cluster randomized trial
71 offering daily oral PrEP among PBFW in Western Kenya (PrIMA-X)[23,24]. Eligibility criteria for PrEP-PP
72 included: ≥ 16 years old, confirmed HIV-negative serostatus by a 4th generation antigen/antibody
73 combination HIV test (Abbott), intention to stay in Cape Town through the postpartum period, and no
74 contraindications to PrEP use. Eligibility criteria for PrIMA-X included: ≥ 15 years old, confirmed HIV and TB
75 negative, intention to reside in the area for at least one year postpartum, and plans to receive postnatal
76 and infant care at the study facility. Enrolment criteria for this subsample included: currently using or
77 having previously used daily oral PrEP; currently pregnant or ≤ 9 months postpartum; and enrolment in
78 PrEP-PP or PrIMA-X.

79

80 **Data collection:** Between September 2021 and February 2022, trained study staff fluent in English and
81 either isiXhosa, Kiswahili, or Luo approached women attending PrEP-PP or PrIMA-X follow-up visits to
82 introduce the study. Study staff then screened participants for study eligibility, obtained written informed
83 consent in English or the participant's local language (isiXhosa, Kiswahili, or Luo), and administered the
84 survey to eligible consenting participants. Study staff asked participants survey questions and recorded
85 responses on a tablet. The survey took 30-40 minutes and was completed on REDCap, a secure web-based
86 platform[25]. Participants received 120 Rand in South Africa (~\$7 USD) or KSh 300 in Kenya (~\$3 USD) for
87 their participation in the study as well as transportation expenses.

88

89 **Survey Measures:**

90 *Participant Sociodemographic Characteristics*

91 We collected (a) basic demographic data (including age, obstetric history, education level, employment,
92 number of sexual partners), (b) HIV risk perception (response to "How would you describe your chances of
93 getting HIV in the next year?" from "no chance at all" to "great chance"), (c) current alcohol use adapted
94 from the Alcohol Use Disorders Identification Test[26,27], (d) PrEP adherence based on 30-day recall (i.e.

95 responding “yes” or “no” to taking PrEP within the past 30 days), (e) clinic access (including transportation
96 method, total travel time, and total transportation cost), and (f) previous use of any contraceptive
97 methods. We also assessed PrEP stigma using a seven-item scale derived from existing literature in which
98 participants responded to statements describing experiences of PrEP stigma via a 5-point Likert scale
99 ranging 0 = “strongly disagree” to 4 = “strongly agree”[28,29].

100 *Current and Future PrEP Preferences*

101 We assessed perceptions of daily oral PrEP by asking participants what they like and dislike about oral PrEP.
102 We described methods of long-acting HIV prevention currently pending regulatory approval or in
103 development, and asked participants about preferences regarding HIV prevention modalities that may be
104 available in the future. We adapted a list of PrEP characteristics from a discrete choice experiment of HIV
105 prevention methods assessed within the Quatro Study[30]. We asked participants to rank the top three
106 most important characteristics of a potential HIV prevention product, the top three most important access-
107 related characteristics, and how frequently they would theoretically use an HIV prevention method.

108 *Long-acting PrEP Preferences*

109 We assessed preferences regarding injectable PrEP and the vaginal ring by asking participants whether
110 they would prefer to switch to the long-acting method or remain on oral PrEP. We then assessed reasons
111 for preferring the long-acting method or oral PrEP.

112

113 **Statistical analyses:** We used descriptive statistics (median, interquartile range [IQR], frequency) to report
114 participant responses, and used Chi-square, Fischer’s Exact, and Wilcoxon rank sum to compare responses
115 between countries. We used univariate and multivariable logistic regression models to assess predictors of
116 preferring a long-acting PrEP method (injection or ring) over oral PrEP (among those with this preference).
117 We adjusted for *a priori* potential confounders (maternal age and country) in the multivariable models.
118 Statistical analyses were conducted with STATA v.17[31].

119

120 **Ethics:** The PrEP-PP study was approved by the Human Research Ethics Committee of the University of
121 Cape Town Faculty of Health Sciences (#297/2018) and by the University of California, Los Angeles
122 Institutional Review Board (IRB#18-001622). The PrIMA-X study was approved by the Kenyatta National
123 Hospital-University of Nairobi Ethics and Research Committee (P73/02/2017) and by the University of
124 Washington Human Subjects Division (STUDY00000438).

125

126 Results

127 Overall, 394 women were enrolled in the study, 190 women from the South African cohort and 204 from
128 the Kenyan cohort. Median ages were 27 (IQR=22-32) and 29 (IQR=25-33) respectively (**Table 1**). Overall,
129 33% of South African participants were pregnant (n=63) while 21% of Kenyan participants were pregnant
130 (n=42), with the remaining in both groups postpartum. Most participants completed some or all secondary
131 school education (total n=326, 83%) although secondary education was more common in South Africa
132 (93%, Kenya 74%, p<0.01). Unemployment was more common in Kenya (Kenya 87%, South Africa 72%,
133 p<0.01). Almost all (95%) women reported having at least one current sexual partner (n=373). Most
134 participants reported that they took at least one dose of PrEP over the previous 30 days at the time of the
135 survey (South Africa 82%, Kenya 68%, p<0.001), and median time on PrEP among current PrEP users was
136 337 days (IQR=263-420) and 308 days (IQR=114-442) among South African and Kenyan participants,
137 respectively.

138 At entry into the parent study, 52% of South African women and 81% of Kenyan women reported any
139 perceived risk of HIV acquisition (p<0.01). More than half endorsed no forms of PrEP stigma (66%,
140 n=251/380), although more women in Kenya endorsed at least one form of PrEP stigma (Kenya 40%, South
141 Africa 27%, p=0.01).

142 At the time of the survey, participants' median travel time to and from the clinic was 30 minutes (IQR=20-
143 40) in South Africa and 55 minutes (IQR=31-60) in Kenya (p<0.01), and median cost to travel to and from
144 the clinic was USD \$1.32 (IQR=1.32-1.32) and \$1.75 (IQR=0.88-2.64) respectively (p=0.01). When asked
145 about any previous experience with contraceptives, women frequently described use of injectable
146 contraceptives (South Africa 94% vs Kenya 66%, p<0.01), followed in South Africa by use of male condoms
147 (n=171, 90%) and contraceptive implants (n=70, 37%). Among women in Kenya, injectable contraceptive
148 was most common (n=134, 66%), followed by the contraceptive implant (n=111, 54%) and then male
149 condoms (n=46, 23%).

150

151 Experiences with Oral PrEP

152 Almost all participants (n=386, 98%) reported efficacy in HIV prevention as a positive characteristic of daily
153 oral PrEP, followed by daily oral PrEP having few or no side effects (n=61, 15%) and being easy to use
154 (n=27, 7%) (**Table 2**). In addition, 10 (5%) participants in Kenya (compared to none in South Africa) liked
155 that oral PrEP was discreet and 5 (2%) participants in South Africa (compared to none in Kenya) reported
156 oral PrEP's safety during breastfeeding as a positive characteristic. Forty-two percent of women in South
157 Africa (n=79) and 56% in Kenya (n=114, p<0.01) disliked at least one attribute about daily oral PrEP. The

158 most frequently reported dislikes included side effects (South Africa 21%, Kenya 30%, $p=0.03$), daily use
159 (South Africa 20%, Kenya 25%, $p=0.20$), and taking it orally (South Africa 6%, Kenya 11%, $p=0.08$).

160

161 **Future PrEP Preferences**

162 When asked to rank characteristics of a potential PrEP product that may be available to them in the future,
163 52% of participants ($n=203$) ranked effectiveness at preventing HIV as the most important, followed by the
164 ability to have a healthy pregnancy ($n=47$, 12%), frequency of use ($n=39$, 10%), tolerability ($n=39$, 10%), and
165 the ability to breastfeed and have a healthy baby ($n=26$, 7%). However, there were country-specific
166 differences in the ranking of several attributes: more women in Kenya ranked HIV prevention highest (78%,
167 South Africa 23%, $p<0.01$), more women in South Africa ranked having a healthy pregnancy (19%, Kenya
168 5%, $p<0.01$), frequency of use (18%, Kenya 2%, $p<0.01$), side effects (16%, Kenya 4%, $p<0.01$), and privacy
169 (6%, Kenya 1%, $p=0.01$) as most important (**Table 3**). When asked to rank access-related characteristics of a
170 potential PrEP product, 52% of participants ranked medication being free as the most important, followed
171 by ease of the process by which the product is obtained, location, and total time it takes to get the
172 product. When asked to rank preferred frequency of PrEP use, participants most frequently preferred once
173 a year ($n=123$, 31%), followed by once per month ($n=62$, 16%), once every 2-3 months ($n=59$, 15%), before
174 sex ($n=53$, 13%), every day ($n=46$, 12%), once every 6 months ($n=45$, 11%), and after sex ($n=6$, 2%). Kenyan
175 women preferred PrEP use once every 6 months, or once every 2-3 months, whereas South African women
176 preferred a product that could be used once a year ($p<0.01$).

177

178 **Preference of long-acting PrEP modalities**

179 Overall, three-fourths of participants ($n=297$, South Africa 74%, Kenya 76%, $p=0.60$) responded that they
180 would prefer to switch to injectable PrEP over remaining on oral PrEP if it were available (**Figure 1**). South
181 African and Kenyan women differed in their reasons for preferring injectable PrEP over oral PrEP:
182 participants in South Africa more commonly preferred it for its longer duration of effectiveness (South
183 Africa 87%, Kenya 42%, $p<0.01$) and not having to take a daily pill (South Africa 57%, Kenya 41%, $p<0.01$),
184 while participants in Kenya were more likely to state reasons of privacy (Kenya 49%, South Africa 5%,
185 $p<0.01$) and not having to carry pills (Kenya 42%, South Africa 13%, $p<0.01$) (**Supplementary Table 1**). The
186 most common concerns regarding injectable PrEP were injection pain and potential side effects. Although
187 overall these concerns were not frequently reported, Kenyan participants were more concerned than
188 South African participants regarding the safety of the new injectable (Kenya 13%, South Africa 4%, $p=0.01$)
189 and its safety for infants if using the injectable while breastfeeding (Kenya 6%, South Africa 0%, $p=0.01$).

190 Fewer women (n=40, 10%) would prefer switching to the vaginal ring over oral PrEP in both South Africa
191 and Kenya (12% and 9% respectively). South African women were interested in the vaginal ring most
192 frequently due to its longer duration (n=14/22, 64%) and not having to remember to take a daily pill
193 (n=12/22, 55%), while most common reasons for preferring the vaginal ring in Kenya were because it was
194 “easy to use” (n=8/18, 44%) or did not involve carrying pills (n=6/18, 33%). Participants were unsure or
195 preferred oral PrEP over the vaginal ring most frequently due to its insertion into the vagina particularly
196 among South African women (South Africa 82%, Kenya 48%, $p<0.01$), potential side effects more so among
197 Kenyan women (South Africa 21%, Kenya 33%, $p=0.02$), and concerns about safety (South Africa 23%,
198 Kenya 27%). Participants in South Africa were also more frequently concerned about the vaginal ring not
199 providing sufficient protection against HIV (14%, Kenya 7%, $p=0.03$).

200 In multivariable analyses adjusting for age and country, preference of a long-acting PrEP method (either
201 injectable PrEP or vaginal ring) over daily oral PrEP was associated with prior use of injectable
202 contraception (aOR=2.48, 95% CI=1.34, 4.57), disliking at least one attribute of daily oral PrEP (aOR=1.72,
203 95% CI=1.05, 2.80), disliking the daily use of oral PrEP (aOR=1.92, 95% CI=1.01, 3.67), and preferring longer
204 duration of effectiveness (aOR=1.58, 95% CI=0.94, 2.65) (**Table 4**). Preferring a long-acting PrEP method
205 over oral PrEP was negatively associated with previous use of the female condom (aOR=0.27, 95% CI=0.07,
206 1.12) and liking taking oral PrEP daily (aOR 0.30, 95% CI=0.07, 1.24).

207

208 **Discussion**

209 We identified a strong theoretical preference for long-acting injectable PrEP among pregnant and
210 postpartum women in Kenya and South Africa. Additionally, about one-half of women reported liking daily
211 oral PrEP, indicating the importance of providing pregnant and postpartum women with choices of
212 modalities. Studies assessing end-user preference among African women of potential HIV prevention
213 methods (multiple vaginally inserted methods, injection, pill) showed that women had varied preference
214 for these HIV prevention modalities, and women described the importance of personal preference in
215 product choice[32-34]. Similar to HIV prevention, studies on contraceptive choice indicate that the best
216 method for an individual depends on their preferences, necessitating a diversity of contraceptive
217 options[35-37]. Our data suggest that the availability of choices to meet personal preferences is essential
218 to improving overall uptake of HIV prevention methods among pregnant and postpartum women as well.
219 Furthermore, women in South Africa and Kenya did not differ in preferences for long-acting PrEP
220 modalities compared to oral PrEP, but did differ in the reasoning behind their preferences, indicating the
221 importance of context-specific implementation when providing HIV prevention modalities.
222 Sociodemographic characteristics and available PrEP modalities differ between countries, indicating that

223 differences between countries in PrEP preferences among pregnant and postpartum women need to be
224 studied and incorporated into country-specific plans for PrEP rollout.

225 Our findings on preference for long-acting injectable PrEP among pregnant and postpartum women, as
226 well as most reasons for their PrEP preferences, align with the existing literature among nonpregnant
227 women. Women also noted need for safety data in pregnancy and lactation in our study, which was
228 distinct for this population. In studies providing hypothetical choices between long-acting PrEP modalities,
229 nonpregnant women from Kenya and South Africa preferred injectable methods of HIV prevention over
230 other modalities, despite similar concerns regarding injection pain[38-40]. In studies assessing acceptability
231 of long-acting injectable PrEP among women within clinical trials in Africa and the United States,
232 participants described acceptability of long-acting injectable PrEP due to its ease of use and long-term
233 protection and would use the method again[41-43], which may suggest that hypothetical acceptability of
234 long-acting injectable PrEP among pregnant and postpartum women may align with its acceptability
235 among nonpregnant women during implementation. Some PrEP preferences identified by women in our
236 study were specific to the pregnancy-postpartum period, such as the importance of safety in pregnancy
237 and infant safety while breastfeeding on PrEP. Previous data have identified the positive impacts of
238 counseling about infant safety on oral PrEP initiation among women in Kenya, highlighting that obtaining
239 further data on pregnancy outcomes and infant safety of CAB-LA, as well as counseling on safety may be
240 beneficial for uptake[18].

241 Pregnant and postpartum women in our study reported that they would prefer to use a long-acting
242 injectable PrEP for privacy and discreetness of this method, highlighting the role of long-acting PrEP to
243 mitigate sociocultural barriers previously identified with oral PrEP use[16-18,44]. Qualitative studies in
244 Kenya and South Africa have described the negative community perception surrounding PrEP use
245 experienced by pregnant and nonpregnant women, particularly due to its association with high-risk sexual
246 behavior as well as being conflated with antiretroviral therapy, leading to concealment of product use[45-
247 47]. A qualitative study assessing oral PrEP perceptions among pregnant and postpartum women in Kenya
248 additionally described fear of male partners becoming violent if discovering their PrEP use, indicating that
249 stigma and negative sentiments towards PrEP within a household may decrease PrEP disclosure and
250 necessitate concealment[48,49]. The availability of a HIV prevention method, such as long-acting injectable
251 PrEP, that does not require daily administration or concealment of physical pills may make it easier for
252 pregnant and postpartum women experiencing PrEP stigma to persist on the HIV prevention method – and
253 has been hypothetically posed by women as a potential solution in previous qualitative work[47]. Long-
254 acting PrEP modalities must be made available in conjunction to other solutions that mitigate community-
255 and individual-level stigma experienced by women in Kenya and South Africa, such as community-facing

256 interventions involving media and educational initiatives, as well as the involving of male partners in HIV
257 prevention and education[41,50].

258 Few pregnant and postpartum women reported preference for the PrEP vaginal ring over oral PrEP, which
259 may be due to unfamiliarity with the method as well as its lower efficacy. Existing acceptability and
260 demonstration studies of the dapivirine ring for HIV prevention show that despite similar initial concerns
261 regarding insertion into the vagina and potential side effects, women in Sub-Saharan Africa who began
262 using vaginal rings for HIV prevention developed familiarity with the method, found it easy to integrate
263 into their lives, and reported willingness to use the method in the future[51-54]. Our data in the context of
264 these studies indicate the importance of education regarding vaginal ring insertion and anticipated side
265 effects when counseling about available HIV prevention modalities, and reemphasize the need for
266 available choice in HIV prevention methods that can be used individually or in combination.

267 Prior use of injectable contraception was associated with a preference for injectable PrEP, indicating that
268 contraceptive knowledge and familiarity with the concept of regular injections as a prevention measure
269 may impact uptake of injectable PrEP among pregnant and postpartum women. Studies assessing
270 acceptability of multipurpose prevention technologies combining HIV and pregnancy prevention similarly
271 showed that injections were preferred compared to a ring or pill-form of combination prevention, and that
272 past experience with similar contraceptive delivery forms was a significant predictor of their method
273 choice[55-57]. Combining HIV prevention education with family planning education may improve uptake of
274 HIV prevention, due to existing familiarity with long-acting contraceptive modalities. Further, the future
275 development of combination prevention methods may improve uptake of HIV prevention.

276 *Limitations*

277 Our study included pregnant and postpartum women with knowledge and experience with oral PrEP. As
278 such, our results may differ from preferences of pregnant and postpartum women without prior
279 experience using PrEP. Our surveys provided a hypothetical choice between PrEP modalities, as some
280 methods are not yet available in South Africa and Kenya (i.e. injectable PrEP in both countries, vaginal ring
281 PrEP in Kenya). Responses may differ from PrEP choices during an implementation offering multiple
282 modalities. Our results may not be generalizable to other settings beyond urban South Africa and Kenya, so
283 further study is necessary on the acceptability of long-acting PrEP among pregnant and postpartum
284 women in other settings.

285

286 **Conclusions**

287 Our study demonstrates that pregnant and postpartum women on oral PrEP may desire a switch to long-
288 acting injectable PrEP as it becomes available in South Africa and Kenya. Women in our study had different
289 PrEP preferences and different reasons for these preferences, indicating the need for client-centered PrEP
290 programs that offer diverse choices for HIV prevention and empower women to make the choice best
291 suited to their needs and lifestyle. Some of these preferences, such as safety for maternal-infant dyad,
292 were specific to the pregnant-postpartum period, while others likely reflected general preferences of
293 women about PrEP. Overall, further efforts are needed to increase choice and accessibility of various PrEP
294 options to benefit the well-being of pregnant and postpartum women and their infants.

295

296 **Conflict of Interest Statement**

297 The PrEP-PP study received the study drug (Truvada®) from Gilead Sciences (Foster City, CA, USA).

298

299 **Authorship**

300 Study was conceived by NJW and designed by NJW, RH, JP, DLJD. NJW oversaw study implementation and
301 data collection, analyzed the data, wrote the first draft of manuscript, and reviewed the manuscript
302 following revision by all co-authors. RM, MM, LG, and NM reviewed the study design, oversaw study
303 implementation and data collection, and assisted with data analysis. CO, CM, RH, JP, and DLJD reviewed
304 the study design, study data, and data analysis. JK, GJ-S, and JP designed the PRIMA-X study, and LM and
305 DLJD designed the PrEP-PP study. All authors contributed to the development of this manuscript, and have
306 read and approved the final manuscript.

307

308 **Acknowledgments**

309 We would like to thank all PrEP-PP and PrIMA-X study participants for their time and perspectives, as well
310 as the PrEP-PP and PrIMA-X project staff, the City of Cape Town Department of Health, Kenyan Ministry of
311 Health, and Siaya and Homa Bay County Governments.

312

313 **Funding**

314 This work was funded by the National Institute of Mental Health: R01MH116771 (DJD, LM), The Eunice
315 Kennedy Shriver National Institute of Child Health and Human Development: 1R01HD106821 (DJD)
316 R01HD100201 (JP), the Fogarty International Center: K01TW011187 (DJD), the National Institute of Nursing
317 Research: R01NR019220 (JP and JK) and the National Institutes of Allergy and Infectious Diseases:
318 R01AI125498 (GJS). The PrEP-PP study received the study drug (Truvada®) from Gilead Sciences (Foster
319 City, CA, USA).

References

1. UNAIDS. (n.d.). Start Free Stay Free AIDS Free - 2020 Progress Report. https://www.unaids.org/sites/default/files/media_asset/start-free-stay-free-aids-free-2020-progress-report_en.pdf
2. Woldesenbet, S., Kufa-Chakezha, T., Lombard, C., Manda, S., Cheyip, M., Ayalew, K., Chirombo, B., Barron, P., Diallo, K., Parekh, B., & Puren, A. (2021). Recent HIV infection among pregnant women in the 2017 antenatal sentinel cross-sectional survey, South Africa: Assay-based incidence measurement. *PLoS One*, 16(4), e0249953. <https://doi.org/10.1371/journal.pone.0249953>
3. le Roux, S. M., Abrams, E. J., Nguyen, K. K., & Myer, L. (2019). HIV incidence during breastfeeding and mother-to-child transmission in Cape Town, South Africa. *AIDS (London, England)*, 33(8), 1399–1401. <https://doi.org/10.1097/QAD.0000000000002224>
4. Sirengo, M., Muthoni, L., Kellogg, T. A., Kim, A. A., Katana, A., Mwanjumba, S., Kimanga, D. O., Maina, W. K., Muraguri, N., Elly, B., Rutherford, G. W., & KAIS Study Group. (2014). Mother-to-child transmission of HIV in Kenya: results from a nationally representative study. *Journal of Acquired Immune Deficiency Syndromes (1999)*, 66 Suppl 1, S66-74. <https://doi.org/10.1097/QAI.0000000000000115>
5. Kharsany, A. B., Frohlich, J. A., Yende-Zuma, N., Mahlase, G., Samsunder, N., Dellar, R. C., Zuma-Mkhonza, M., Karim, S. S. A., & Karim, Q. A. (2015). Trends in HIV prevalence in pregnant women in rural South Africa. *Journal of Acquired Immune Deficiency Syndromes (1999)*, 70(3), 289–295. <https://doi.org/10.1097/QAI.0000000000000761>
6. Pettifor, A. E., Rees, H. V., Kleinschmidt, I., Steffenson, A. E., MacPhail, C., Hlongwa-Madikizela, L., Vermaak, K., & Padian, N. S. (2005). Young people's sexual health in South Africa: HIV prevalence and sexual behaviors from a nationally representative household survey. *AIDS (London, England)*, 19(14), 1525–1534. <https://doi.org/10.1097/01.aids.0000183129.16830.06>
7. Ryan, J. H., Young, A., Musara, P., Reddy, K., Macagna, N., Guma, V., Seyama, L., Piper, J., van der Straten, A., & MTN- 041/MAMMA Study Team. (2022). Sexual Attitudes, Beliefs, Practices, and HIV Risk During Pregnancy and Post-delivery: A Qualitative Study in Malawi, South Africa, Uganda, and Zimbabwe. *AIDS and Behavior*, 26(3), 996–1005. <https://doi.org/10.1007/s10461-021-03454-y>
8. Varga, C. A. (2003). How gender roles influence sexual and reproductive health among South African adolescents. *Studies in Family Planning*, 34(3), 160–172. <https://doi.org/10.1111/j.1728-4465.2003.00160.x>
9. Woldesenbet, S., Kufa-Chakezha, T., Lombard, C., Manda, S., Cheyip, M., Ayalew, K., Chirombo, B., Barron, P., Diallo, K., Parekh, B., & Puren, A. (2021). Recent HIV infection among pregnant women in the 2017 antenatal sentinel cross-sectional survey, South Africa: Assay-based incidence measurement. *PLoS One*, 16(4), e0249953. <https://doi.org/10.1371/journal.pone.0249953>
10. le Roux, S. M., Abrams, E. J., Nguyen, K. K., & Myer, L. (2019). HIV incidence during breastfeeding and mother-to-child transmission in Cape Town, South Africa. *AIDS (London, England)*, 33(8), 1399–1401. <https://doi.org/10.1097/QAD.0000000000002224>
11. AVAC: Global Advocacy for HIV Prevention. (2022). *A map-based tool to explore trends in oral PrEP use globally as countries introduce and scale up PrEP programs*. PrEPWatch: The Global PrEP Tracker. <https://data.prepwatch.org/>
12. Joseph Davey, D. L., Mvududu, R., Mashele, N., Lesosky, M., Khadka, N., Bekker, L., Gorbach, P., Coates, T. J., & Myer, L. (2022). Early pre-exposure prophylaxis (PrEP) initiation and continuation among pregnant and postpartum women in antenatal care in Cape Town, South Africa. *Journal of the International AIDS Society*, 25(2), e25866. <https://doi.org/10.1002/jia2.25866>
13. Kinuthia, J., Pintye, J., Abuna, F., Mugwanya, K. K., Lagat, H., Onyango, D., Begnel, E., Dettinger, J., Baeten, J. M., John-Stewart, G., Aquino, A. C., Ochieng, S. J., Lipesa, A. M., Naidu, A. L., Kamau, A., Njoroge, A. W., Okeah, B. O., Makabwa, C. B., Atieno, C. C., ... Fondo, Y. F. (2020). Pre-exposure prophylaxis uptake and early continuation among pregnant and post-partum women within maternal and child health clinics in Kenya: results from an implementation programme. *The Lancet HIV*, 7(1), e38–e48. [https://doi.org/10.1016/S2352-3018\(19\)30335-2](https://doi.org/10.1016/S2352-3018(19)30335-2)

14. Pintye J., Davey D. L. J., Wagner A. D., et al. Defining gaps in pre-exposure prophylaxis delivery for pregnant and postpartum women in high-burden settings using an implementation science framework. *Lancet HIV*. 2020;7(8):e582-e592. doi:10.1016/S2352-3018(20)30102-8
15. Davey D. L. J., Nyemba D., Castillo-Mancilla J., Weisner L., Norman J., Mvududu R., Mashele N., Johnson L. F., Bekker L., Gorbach P., Coates T. J., Myer L. (2022). Objective versus self-reported adherence to daily pre-exposure prophylaxis (PrEP) among pregnant and postpartum women in South Africa. *Lancet HIV*. Submitted.
16. Beesham, I., Dovel, K., Mashele, N., Bekker, L.-G., Gorbach, P., Coates, T. J., Myer, L., & Joseph Davey, D. L. (2022). Barriers to Oral HIV Pre-exposure Prophylaxis (PrEP) Adherence Among Pregnant and Post-partum Women from Cape Town, South Africa. *AIDS and Behavior*. <https://doi.org/10.1007/s10461-022-03652-2>
17. Beesham, I., Heffron, R., Evans, S., Baeten, J. M., Smit, J., Beksinska, M., & Mansoor, L. E. (2021). Exploring the Use of Oral Pre-exposure Prophylaxis (PrEP) Among Women from Durban, South Africa as Part of the HIV Prevention Package in a Clinical Trial. *AIDS and Behavior*, 25(4), 1112–1119. <https://doi.org/10.1007/s10461-020-03072-0>
18. Pintye, J., O'Malley, G., Kinuthia, J., Abuna, F., Escudero, J. N., Mugambi, M., Awuor, M., Dollah, A., Dettinger, J. C., Kohler, P., John-Stewart, G., & Beima-Sofie, K. (2021). Influences on early discontinuation and persistence of daily oral PrEP use among Kenyan adolescent girls and young women: a qualitative evaluation from a PrEP implementation program. *Journal of Acquired Immune Deficiency Syndromes (1999)*, 86(4), e83–e89. <https://doi.org/10.1097/QAI.0000000000002587>
19. Delany-Moretlwe S, Hughes JP, Bock P, Ouma SG, Hunidzarira P, Kalonji D, Kayange N, Makhema J, Mandima P, Mathew C, Spooner E, Mpendo J, Mukwekwerere P, Mgodini N, Ntege PN, Nair G, Nakabiito C, Nuwagaba-Biribonwoha H, Panchia R, Singh N, Siziba B, Farrior J, Rose S, Anderson PL, Eshleman SH, Marzinke MA, Hendrix CW, Beigel-Orme S, Hosek S, Tolley E, Sista N, Adeyeye A, Rooney JF, Rinehart A, Spreen WR, Smith K, Hanscom B, Cohen MS, Hosseinipour MC; HPTN 084 study group. Cabotegravir for the prevention of HIV-1 in women: results from HPTN 084, a phase 3, randomised clinical trial. *Lancet*. 2022 May 7;399(10337):1779-1789. doi: 10.1016/S0140-6736(22)00538-4. Epub 2022 Apr 1. Erratum in: *Lancet*. 2022 May 7;399(10337):1778. PMID: 35378077.
20. Delany-Moretlwe, S., Hughes, J., Guo, X., Hanscom, B., Hendrix, C. W., Farrior, J., Berhanu, R. H., Rinehart, A. R., Ford, S. L., Rooney, J. F., Adeyeye, A., Landovitz, R. J., Cohen, M. S., Hosseinipour, M. C., & Marzinke, M. (2022, February 12). Evaluation of CAB-LA safety and PK in pregnant women in the blinded phase of HPTN 084. CROI 2022, virtual meeting. <https://www.croiconference.org/abstract/evaluation-of-cab-la-safety-and-pk-in-pregnant-women-in-the-blinded-phase-of-hptn-084/>
21. Patel, P., Ford, S. L., Baker, M., Meyer, C., Garside, L., D'Amico, R., Van Solingen-Ristea, R., Crauwels, H., Polli, J., Seal, C., Thiagarajah, S., Birmingham, E., Spreen, W., Baugh, B., Bosse, M., & Vannappagari, V. (2021). 885. Pregnancy Outcomes and Pharmacokinetics in Pregnant Women Living with HIV Exposed to Long-Acting Cabotegravir and Rilpivirine in Clinical Trials. *Open Forum Infectious Diseases*, 8(Suppl 1), S534. <https://doi.org/10.1093/ofid/ofab466.1080>
22. Baeten, J. M., Palanee-Phillips, T., Mgodini, N. M., Mayo, A. J., Szydlo, D. W., Ramjee, G., Gati Mirembe, B., Mhlanga, F., Hunidzarira, P., Mansoor, L. E., Siva, S., Govender, V., Makanani, B., Naidoo, L., Singh, N., Nair, G., Chinula, L., Parikh, U. M., Mellors, J. W., ... MTN-025/HOPE Study Team. (2021). Safety, uptake, and use of a dapivirine vaginal ring for HIV-1 prevention in African women (HOPE): an open-label, extension study. *The Lancet. HIV*, 8(2), e87–e95. [https://doi.org/10.1016/S2352-3018\(20\)30304-0](https://doi.org/10.1016/S2352-3018(20)30304-0)
23. Dettinger, J. C., Kinuthia, J., Pintye, J., Mwongeli, N., Gómez, L., Richardson, B. A., Barnabas, R., Wagner, A. D., O'Malley, G., Baeten, J. M., & John-Stewart, G. (2019). PrEP Implementation for Mothers in Antenatal Care (PrIMA): study protocol of a cluster randomised trial. *BMJ Open*, 9(3), e025122. <https://doi.org/10.1136/bmjopen-2018-025122>
24. Joseph Davey, D. L., Mvududu, R., Mashele, N., Lesosky, M., Khadka, N., Bekker, L.-G., Gorbach, P., Coates, T. J., & Myer, L. (2022). Early pre-exposure prophylaxis (PrEP) initiation and continuation

- among pregnant and postpartum women in antenatal care in Cape Town, South Africa. *Journal of the International AIDS Society*, 25(2), e25866. <https://doi.org/10.1002/jia2.25866>
25. Harris, P. A., Taylor, R., Thielke, R., Payne, J., Gonzalez, N., & Conde, J. G. (2009). Research electronic data capture (REDCap)--a metadata-driven methodology and workflow process for providing translational research informatics support. *Journal of Biomedical Informatics*, 42(2), 377–381. <https://doi.org/10.1016/j.jbi.2008.08.010>
 26. Bush K, Kivlahan DR, McDonell MB, Fihn SD, Bradley KA. The AUDIT alcohol consumption questions (AUDIT-C): an effective brief screening test for problem drinking. Ambulatory Care Quality Improvement Project (ACQUIP). Alcohol Use Disorders Identification Test. *Arch Intern Med* 1998; **158**(16): 1789-95.
 27. Kader R, Seedat S, Koch JR, Parry CD. A preliminary investigation of the AUDIT and DUDIT in comparison to biomarkers for alcohol and drug use among HIV-infected clinic attendees in Cape Town, South Africa. *Afr J Psychiatry (Johannesbg)* 2012; **15**(5): 346-51.
 28. Klein, H., & Washington, T. A. (2019). The Pre-Exposure Prophylaxis (PrEP) Stigma Scale: Preliminary findings from a pilot study. *International Public Health Journal*, 11(2), 185–195. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7034943/>
 29. Munthali, R. J., Stangl, A. L., Baron, D., Barré, I., Harvey, S., Ramskin, L., Colombini, M., Naicker, N., Kapiga, S., Delany-Moretlwe, S., & the EMPOWER study team. (2022). Prevalence and Risk Factors of PrEP Use Stigma Among Adolescent Girls and Young Women in Johannesburg, South Africa and Mwanza, Tanzania Participating in the EMPOWER Trial. *AIDS and Behavior*. <https://doi.org/10.1007/s10461-022-03721-6>
 30. Browne, E. N., Montgomery, E. T., Mansfield, C., Boeri, M., Mange, B., Beksinska, M., Schwartz, J. L., Clark, M. R., Doncel, G. F., Smit, J., Chirenje, Z. M., & van der Straten, A. (2020). Efficacy is Not Everything: Eliciting Women’s Preferences for a Vaginal HIV Prevention Product Using a Discrete-Choice Experiment. *AIDS and Behavior*, 24(5), 1443–1451. <https://doi.org/10.1007/s10461-019-02715-1>
 31. StataCorp. 2021. *Stata Statistical Software: Release 17*. College Station, TX: StataCorp LLC.
 32. Montgomery, E. T., Beksinska, M., Mgodhi, N., Schwartz, J., Weinrib, R., Browne, E. N., Mphili, N., Musara, P., Jaggernath, M., Ju, S., Smit, J., Chirenje, Z. M., Doncel, G. F., & van der Straten, A. (2019). End-user preference for and choice of four vaginally delivered HIV prevention methods among young women in South Africa and Zimbabwe: the Quatro Clinical Crossover Study. *Journal of the International AIDS Society*, 22(5), e25283. <https://doi.org/10.1002/jia2.25283>
 33. van der Straten, A., Ryan, J. H., Reddy, K., Etima, J., Taulo, F., Mutero, P., Taylor, J., Piper, J., Musara, P., & MTN-041/MAMMA Study Team. (2020). Influences on willingness to use vaginal or oral HIV PrEP during pregnancy and breastfeeding in Africa: the multisite MAMMA study. *Journal of the International AIDS Society*, 23(6), e25536. <https://doi.org/10.1002/jia2.25536>
 34. Shapley-Quinn, M. K., Manenzhe, K. N., Agot, K., Minnis, A. M., & van der Straten, A. (2019). “We are not the same”: African women’s view of multipurpose prevention products in the TRIO clinical study. *International Journal of Women’s Health*, 11, 97–107. <https://doi.org/10.2147/IJWH.S185712>
 35. Chappell, C. A., Harkoo, I., Szydlo, D. W., Bunge, K. E., Singh, D., Nakabiito, C., Mhlanga, F., Kamira, B., Piper, J. M., Balkus, J. E., & Hillier, S. L. (2019). Contraceptive method switching among women living in sub-Saharan Africa participating in an HIV-1 prevention trial: a prospective cohort study. *Contraception*, 100(3), 214–218. <https://doi.org/10.1016/j.contraception.2019.06.006>
 36. Clark, H., RamaRao, S., Unthank, C., Machiyama, K., & Thatte, N. (2017). *Family Planning Evidence Brief: Expanding Contraceptive Choice* (WHO/RHR/17.14 Rev.1). World Health Organization. <http://apps.who.int/iris/bitstream/handle/10665/255865/WHO-RHR-17.14-eng.pdf?sequence=1>
 37. Dehlendorf, C., Levy, K., Kelley, A., Grumbach, K., & Steinauer, J. (2013). Women’s preferences for contraceptive counseling and decision making. *Contraception*, 88(2), 250–256. <https://doi.org/10.1016/j.contraception.2012.10.012>
 38. Minnis, A. M., Atujuna, M., Browne, E. N., Ndwayana, S., Hartmann, M., Sindelo, S., Ngcwayi, N., Boeri, M., Mansfield, C., Bekker, L.-G., & Montgomery, E. T. (2020). Preferences for long-acting Pre-Exposure

- Prophylaxis (PrEP) for HIV prevention among South African youth: results of a discrete choice experiment. *Journal of the International AIDS Society*, 23(6), e25528. <https://doi.org/10.1002/jia2.25528>
39. Quaife, M., Eakle, R., Cabrera Escobar, M. A., Vickerman, P., Kilbourne-Brook, M., Mvundura, M., Delany-Moretlwe, S., & Terris-Prestholt, F. (2018). Divergent Preferences for HIV Prevention: A Discrete Choice Experiment for Multipurpose HIV Prevention Products in South Africa. *Medical Decision Making: An International Journal of the Society for Medical Decision Making*, 38(1), 120–133. <https://doi.org/10.1177/0272989X17729376>
 40. Shapley-Quinn, M. K., Manenzhe, K. N., Agot, K., Minnis, A. M., & van der Straten, A. (2019). “We are not the same”: African women’s view of multipurpose prevention products in the TRIO clinical study. *International Journal of Women’s Health*, 11, 97–107. <https://doi.org/10.2147/IJWH.S185712>
 41. Bekker, L. G., Li, S., Pathak, S., Tolley, E. E., Marzinke, M. A., Justman, J. E., Mgodi, N. M., Chirenje, M., Swaminathan, S., Adeyeye, A., Fariior, J., Hendrix, C. W., Piwowar-Manning, E., Richardson, P., Eshelman, S. H., Redinger, H., Williams, P., Sista, N. D., & HPTN 076 Study Team. (2020). Safety and tolerability of injectable Rilpivirine LA in HPTN 076: A phase 2 HIV pre-exposure prophylaxis study in women. *EClinicalMedicine*, 21, 100303. <https://doi.org/10.1016/j.eclinm.2020.100303>
 42. Tolley, E. E., Li, S., Zangeneh, S. Z., Atujuna, M., Musara, P., Justman, J., Pathak, S., Bekker, L.-G., Swaminathan, S., Stanton, J., Fariior, J., & Sista, N. (2019). Acceptability of a long-acting injectable HIV prevention product among US and African women: findings from a phase 2 clinical Trial (HPTN 076). *Journal of the International AIDS Society*, 22(10), e25408. <https://doi.org/10.1002/jia2.25408>
 43. Minnis, A. M., Browne, E. N., Boeri, M., Agot, K., van der Straten, A., Ahmed, K., Weinrib, R., & Mansfield, C. (2019). Young Women’s Stated Preferences for Biomedical HIV Prevention: Results of a Discrete Choice Experiment in Kenya and South Africa. *Journal of Acquired Immune Deficiency Syndromes (1999)*, 80(4), 394–403. <https://doi.org/10.1097/QAI.0000000000001945>
 44. Minnis, A. M., Krogstad, E., Shapley-Quinn, M. K., Agot, K., Ahmed, K., Danielle Wagner, L., van der Straten, A., & TRIO Study Team. (2021). Giving voice to the end-user: input on multipurpose prevention technologies from the perspectives of young women in Kenya and South Africa. *Sexual and Reproductive Health Matters*, 29(1), 1927477. <https://doi.org/10.1080/26410397.2021.1927477>
 45. Escudero, J. N., Dettinger, J. C., Pintye, J., Kinuthia, J., Lagat, H., Abuna, F., Kohler, P., Baeten, J. M., O’Malley, G., John-Stewart, G. C., & Beima-Sofie, K. M. (2020). Community Perceptions About Use of Pre-exposure Prophylaxis Among Adolescent Girls and Young Women in Kenya. *The Journal of the Association of Nurses in AIDS Care: JANAC*, 31(6), 669–677. <https://doi.org/10.1097/JNC.000000000000191>
 46. Bergam, S., Harrison, A. D., Benghu, N., Khumalo, S., Tesfay, N., Exner, T., Miller, L., Dolezal, C., Hanass-Hancock, J., & Hoffman, S. (2022). Women’s Perceptions of HIV- and Sexuality-Related Stigma in Relation to PrEP: Qualitative Findings from the Masibambane Study, Durban, South Africa. *AIDS and Behavior*. <https://doi.org/10.1007/s10461-022-03632-6>
 47. Velloza, J., Khoza, N., Scorgie, F., Chitukuta, M., Mutero, P., Mutiti, K., Mangxilana, N., Nobula, L., Bulterys, M. A., Atujuna, M., Hosek, S., Heffron, R., Bekker, L.-G., Mgodi, N., Chirenje, M., Celum, C., Delany-Moretlwe, S., & HPTN 082 study group. (2020). The influence of HIV-related stigma on PrEP disclosure and adherence among adolescent girls and young women in HPTN 082: a qualitative study. *Journal of the International AIDS Society*, 23(3), e25463. <https://doi.org/10.1002/jia2.25463>
 48. Pintye, J., Beima-Sofie, K. M., Makabong’O, P. A., Njoroge, A., Trinidad, S. B., Heffron, R. A., Baeten, J. M., Celum, C., Matemo, D., Kinuthia, J., Kelley, M. C., & John-Stewart, G. C. (2018). HIV-Uninfected Kenyan Adolescent and Young Women Share Perspectives on Using Pre-Exposure Prophylaxis During Pregnancy. *AIDS Patient Care and STDs*, 32(12), 538–544. <https://doi.org/10.1089/apc.2018.0058>
 49. Rousseau, E., Katz, A. W. K., O’Rourke, S., Bekker, L.-G., Delany-Moretlwe, S., Bukusi, E., Travill, D., Omollo, V., Morton, J. F., O’Malley, G., Haberer, J. E., Heffron, R., Johnson, R., Celum, C., Baeten, J. M., & van der Straten, A. (2021). Adolescent girls and young women’s PrEP-user journey during an implementation science study in South Africa and Kenya. *PLoS One*, 16(10), e0258542. <https://doi.org/10.1371/journal.pone.0258542>

50. Moran, A., Mashele, N., Mvududu, R., Gorbach, P., Bekker, L.-G., Coates, T. J., Myer, L., & Joseph Davey, D. (2022). Maternal PrEP Use in HIV-Uninfected Pregnant Women in South Africa: Role of Stigma in PrEP Initiation, Retention and Adherence. *AIDS and Behavior*, 26(1), 205–217. <https://doi.org/10.1007/s10461-021-03374-x>
51. Mayo, A. J., Browne, E. N., Montgomery, E. T., Torjesen, K., Palanee-Phillips, T., Jeenaarain, N., Seyama, L., Woeber, K., Harkoo, I., Reddy, K., Tembo, T., Mutero, P., Tauya, T., Chitukuta, M., Gati Mirembe, B., Soto-Torres, L., Brown, E. R., Baeten, J. M., van der Straten, A., & MTN-020/ASPIRE study team. (2021). Acceptability of the Dapivirine Vaginal Ring for HIV-1 Prevention and Association with Adherence in a Phase III Trial. *AIDS and Behavior*, 25(8), 2430–2440. <https://doi.org/10.1007/s10461-021-03205-z>
52. Montgomery, E. T., van der Straten, A., Chitukuta, M., Reddy, K., Woeber, K., Atujuna, M., Bekker, L.-G., Etima, J., Nakyanzi, T., Mayo, A. J., Katz, A., Laborde, N., Grossman, C. I., Soto-Torres, L., Palanee-Phillips, T., Baeten, J. M., & MTN-020/ASPIRE Study. (2017). Acceptability and use of a dapivirine vaginal ring in a phase III trial. *AIDS (London, England)*, 31(8), 1159–1167. <https://doi.org/10.1097/QAD.0000000000001452>
53. Nel, A., Bekker, L.-G., Bukusi, E., Hellström, E., Kotze, P., Louw, C., Martinson, F., Masenga, G., Montgomery, E., Ndaba, N., van der Straten, A., van Niekerk, N., & Woodsong, C. (2016). Safety, Acceptability and Adherence of Dapivirine Vaginal Ring in a Microbicide Clinical Trial Conducted in Multiple Countries in Sub-Saharan Africa. *PloS One*, 11(3), e0147743. <https://doi.org/10.1371/journal.pone.0147743>
54. van der Straten, A., Ryan, J. H., Reddy, K., Etima, J., Taulo, F., Mutero, P., Taylor, J., Piper, J., Musara, P., & MTN-041/MAMMA Study Team. (2020). Influences on willingness to use vaginal or oral HIV PrEP during pregnancy and breastfeeding in Africa: the multisite MAMMA study. *Journal of the International AIDS Society*, 23(6), e25536. <https://doi.org/10.1002/jia2.25536>
55. Minnis, A. M., Browne, E. N., Boeri, M., Agot, K., van der Straten, A., Ahmed, K., Weinrib, R., & Mansfield, C. (2019). Young Women’s Stated Preferences for Biomedical HIV Prevention: Results of a Discrete Choice Experiment in Kenya and South Africa. *Journal of Acquired Immune Deficiency Syndromes (1999)*, 80(4), 394–403. <https://doi.org/10.1097/QAI.0000000000001945>
56. van der Straten, A., Agot, K., Ahmed, K., Weinrib, R., Browne, E. N., Manenzhe, K., Owino, F., Schwartz, J., Minnis, A., & TRIO Study Team. (2018). The Tablets, Ring, Injections as Options (TRIO) study: what young African women chose and used for future HIV and pregnancy prevention. *Journal of the International AIDS Society*, 21(3), e25094. <https://doi.org/10.1002/jia2.25094>
57. Weinrib, R., Minnis, A., Agot, K., Ahmed, K., Owino, F., Manenzhe, K., Cheng, H., & van der Straten, A. (2018). End-Users’ Product Preference Across Three Multipurpose Prevention Technology Delivery Forms: Baseline Results from Young Women in Kenya and South Africa. *AIDS and Behavior*, 22(1), 133–145. <https://doi.org/10.1007/s10461-017-1911-6>

Table 1: Demographics and health characteristics of pregnant and postpartum women with experience taking oral PrEP, South Africa and Kenya, September 2021 – February 2022 (N=394 women)

	Overall (N=394, %)	South Africa (n=190, %)	Kenya (n=204, %)	p-value
Age (median, IQR)	28 [24-32]	27 [22-32]	29 [25-33]	<0.01
Pregnant (n, %)	105 (27)	63 (33)	42 (21)	0.01
Postpartum (n, %)	289 (73)	127 (67)	162 (79)	0.01
Days on oral PrEP (median, IQR)	335 [168-420]	337 [263-420]	308 [114-442]	0.04
Last grade completed (n, %)				
Primary school (Grades 1-6)	28 (7)	2 (1)	26 (13)	<0.01
Some secondary school (Grades 7-11)	236 (60)	106 (56)	130 (64)	
Completed secondary school	90 (23)	70 (37)	20 (9)	
Some tertiary	16 (4)	8 (4)	8 (4)	
Completed tertiary	24 (6)	4 (2)	20 (10)	
Currently employed (formally or informally)? (n, %)				
No	313 (79)	136 (72)	177 (87)	<0.01
Yes	80 (20)	54 (28)	26 (13)	
Prefer not to answer	1 (1)	0 (0)	1 (1)	
Currently have at least one sexual partner (n, %)				
No	21 (5)	15 (8)	6 (3)	0.03
Yes	373 (95)	175 (92)	198 (97)	
HIV Risk Perception [†] (n, %)				
No risk at all	121/380 (32)	84/176 (48)	37 (18)	<0.01
Small chance	145/380 (44)	56/176 (32)	89 (44)	
Moderate chance	89/380 (34)	20/176 (11)	69 (34)	
Great chance	23/380 (6)	16/176 (9)	7 (3)	
Prefer not to answer	2/380 (1)	0/176 (0)	2 (1)	
Current alcohol use (n, %)				
Never	363/380 (96)	164/176 (93)	199 (98)	0.31
Monthly or less	11/380 (3)	8/176 (5)	3 (2)	
2-4 times a month	5/380 (1)	3/176 (2)	2 (1)	
2-3 times a week	1/380 (1)	1/176 (1)	0 (0)	
4 or more times a week	0 (0)	0 (0)	0 (0)	
HIV PrEP Stigma [‡] (n, %)				
Endorsed 0 forms of stigma	251/380 (66)	128/176 (73)	123 (60)	0.01
Endorsed >1 form of stigma	129/380 (34)	48/176 (27)	81 (40)	
Any oral PrEP use over past 30 days (n, %)				
No	100 (25)	34 (18)	66 (32)	<0.01
Yes	294 (75)	156 (82)	138 (68)	
Clinic transportation (n, %)				
Walking	31 (8)	16 (8)	15 (7)	<0.01
Taxi/Minibus	206 (52)	172 (91)	34 (17)	
Private car	3 (1)	2 (1)	1 (1)	
Motorbike	152 (38)	0 (0)	152 (75)	
Other	2 (1)	0 (0)	2 (1)	
Total travel time to clinic and return (minutes, median, IQR)	40 [30-60]	30 [20.0-40.0]	55 [31.0-60.0]	<0.01
Cost to travel to clinic and return (USD, median, IQR)	1.32 [1.31-1.74]	1.32 [1.32-1.32]	1.75 [0.88-2.64]	0.02

[†] Participants were asked “How would you describe your chances of getting HIV in the next year?” with the option to select “No risk at all,” “Small chance,” “Moderate chance,” “Great chance,” or “Prefer not to answer.”

[‡] Participants were asked to respond on a 5-point Likert scale from “Strongly Disagree” to “Strongly Agree” to 7 statements on potential stigma experienced regarding PrEP use (i.e. “I feel ashamed of using PrEP,” “I feel embarrassed about using PrEP”).

Have you ever used any of the following family planning methods? (n, %)

Male condom	217 (55)	171 (90)	46 (23)	<0.01
Oral contraceptive pill	98 (25)	42 (22)	56 (27)	0.22
Injectable contraceptive	312 (79)	178 (94)	134 (66)	<0.01
Contraceptive implant	181 (46)	70 (37)	111 (54)	<0.01
Female condom	8 (2)	6 (3)	2 (1)	0.97
Vaginal contraceptive ring	2 (1)	0 (0)	2 (1)	0.27
IUD/loop	6 (2)	3 (2)	3 (2)	0.69
Other (tubal ligation)	2 (1)	0 (0)	2 (1)	0.27
None	11 (3)	1 (1)	9 (4)	0.01

Table 2: Likes and dislikes regarding daily oral PrEP in pregnant and postpartum women with experience taking oral PrEP, South Africa and Kenya, September 2021 – February 2022

Oral PrEP likes	Overall (N=394)	South Africa (n=190)	Kenya (n=204)	p-value
HIV prevention	386 (98)	186 (98)	200 (98)	0.92
PrEP has few/no side effects	61 (15)	35 (18)	26 (13)	0.12
Ease of use	27 (7)	16 (8)	11 (5)	0.23
No interruption of sex (as is needed for condoms)	16 (4)	5 (3)	11 (5)	0.17
Easy to hide	10 (3)	0 (0)	10 (5)	<0.01
Take it daily	8 (2)	5 (3)	3 (2)	0.88
Taken orally	7 (2)	5 (3)	2 (1)	0.95
PrEP is safe for the baby	5 (1)	5 (3)	0 (0)	0.03
Other (e.g., overall safety, increased appetite, peaceful sleep)	4 (1)	4 (2)	0 (0)	0.05
Nothing	1 (1)	0 (0)	1 (1)	0.52
Oral PrEP dislikes	Overall (N=394)	South Africa (n=190)	Kenya (n=204)	p-value
Side effects	100 (25)	39 (21)	61 (30)	0.03
Must take it daily	90 (23)	38 (20)	52 (25)	0.20
Must take orally	35 (9)	12 (6)	23 (11)	0.08
Pill size is too big	12 (3)	9 (5)	3 (2)	0.99
No STI prevention	10 (3)	4 (2)	6 (3)	0.42
Not discreet	9 (2)	0 (0)	9 (4)	<0.01
Other (e.g., general dislike, pill taste, pill smell)	3 (1)	2 (1)	1 (1)	0.90
Nothing	201 (51)	111 (58)	90 (44)	<0.01

Table 3: Ranked characteristics of potential HIV prevention products among pregnant and postpartum women with experience taking oral PrEP, South Africa and Kenya, September 2021 – February 2022

Most important characteristic of a potential HIV prevention product (ranked #1)	Overall (N=394)	South Africa (n=190)	Kenya (n=204)	p-value
Effective at preventing HIV	203 (52)	44 (23)	159 (78)	<0.01
Healthy pregnancy	47 (12)	36 (19)	11 (5)	<0.01
How frequently it is used (e.g. before sex, once a day, once a month)	39 (10)	35 (18)	4 (2)	<0.01
Side effects	39 (10)	31 (16)	8 (4)	<0.01
Ability to breastfeed and have healthy baby	26 (7)	15 (8)	11 (5)	0.32
How it is used (e.g. vaginal ring, injected, pill)	25 (6)	16 (8)	9 (4)	0.10
Privacy (from partner)	13 (3)	11 (6)	2 (1)	0.01
Other (not forgotten easily, overall safety)	2 (1)	2 (1)	0 (0)	0.23
Most important access-related characteristic of a potential HIV prevention product (ranked #1)				
Free of charge	203 (52)	104 (55)	99 (49)	0.22
How easy it is to obtain	79 (20)	43 (23)	36 (18)	0.22
Where to pick up (clinic, pharmacy, community)	48 (12)	28 (15)	20 (10)	0.14
Total time it takes to get product	31 (8)	15 (8)	16 (8)	0.99
Most preferable frequency of HIV prevention method (ranked #1)				
Before sex	53 (13)	30 (16)	23 (11)	0.19
After sex	6 (2)	5 (3)	1 (1)	0.10
Every day	46 (12)	26 (14)	20 (10)	0.23
Once per month	62 (16)	25 (13)	37 (18)	0.18
Once every 2-3 months	59 (15)	17 (9)	42 (21)	<0.01
Once every 6 months	45 (11)	11 (6)	34 (17)	<0.01
Once yearly	123 (31)	76 (40)	47 (23)	<0.01

Figure 1: Theoretical acceptability of long-acting PrEP methods versus daily oral PrEP by pregnant and postpartum women with experience taking oral PrEP, Kenya and South Africa, September 2021 – February 2022 (N=394 women)





Table 4: Factors associated with of long-acting PrEP preference vs. oral PrEP among pregnant and postpartum women with experience taking oral PrEP, N=394

	Summary Statistics					
	Wants long-acting (n=305, %)	Wants oral PrEP (n=89, %)	Unadjusted OR (95% CI)	p-value	Adjusted OR [†] (95% CI)	p-value
<i>Maternal age (median, IQR) years</i>	28 [24-32]	27 [23-31]	1.03 [0.99-1.08]	0.11	1.04 [0.99, 1.08]	0.11
≥25 years	221 (72)	59 (66)	1.34 [0.81-2.22]	0.26	1.35 [0.81-2.27]	0.25
<25 years	84 (28)	30 (34)				
<i>Country</i>						
Kenya	158 (52)	46 (52)	1.01 [0.63-1.61]	0.98	0.93 [0.57, 1.51]	0.77
South Africa	147 (48)	43 (48)				
<i>Pregnancy status</i>						
Pregnant	78 (26)	27 (30)	0.79 [0.47-1.33]	0.37	0.82 [0.48, 1.39]	0.46
Postpartum	227 (74)	62 (70)				
<i>Time on PrEP (median, IQR) days</i>	331 [168-422]	336 [185-420]	1.00 [1.00-1.00]	0.90	1.00 [1.00-1.00]	0.78
<i>Last grade completed (ref: primary school)</i>	27 (9)	10 (11)	<i>ref</i>	<i>ref</i>	<i>ref</i>	<i>ref</i>
Some secondary	178 (58)	64 (72)	1.20 [0.55-2.64]	0.64	1.12 [0.52, 2.74]	0.67
Completed secondary	72 (24)	17 (19)	1.48 [0.61-3.61]	0.39	1.62 [0.61, 4.32]	0.34
Some or all tertiary	20 (7)	3 (3)	1.78 [0.53-5.94]	0.35	1.68 [0.49, 5.79]	0.41
<i>Currently employed (formally or informally)</i>						
Employed	61/304 (20)	19 (21)	0.93 [0.52-1.65]	0.79	0.81 [0.44-1.49]	0.49
Not employed	243/304 (80)	70 (79)				
<i>At least one sexual partner</i>						
≥1 sexual partner	288 (94)	85 (96)	0.80 [0.26-2.43]	0.69	0.75 [0.24-2.30]	0.61
0 sexual partners	16 (5)	4 (4)				
<i>PrEP stigma (median, IQR)</i>	14 [13-17]	15 [13-16]	1.02 [0.96-1.09]	0.56	1.03 [0.96-1.10]	0.45
Endorsed 0 stigma	193/293 (66)	58/87 (67)	1.03 [0.62-1.72]	0.89	1.06 [0.63-1.77]	0.83
Endorsed ≥1 stigma statement	100/293 (34)	29/87 (33)				
<i>HIV Risk Perception</i>						
Any perceived HIV risk	194/291 (67)	63/87 (72)	0.76 [0.45, 1.29]	0.31	0.75 [0.43, 1.31]	0.31
No perceived HIV risk	97/291 (33)	24/87 (28)				
<i>Alcohol use</i>						
Endorses any alcohol use	12/293 (4)	5/87 (6)	0.70 [0.24-2.05]	0.52	0.73 [0.25-2.17]	0.58
Does not endorse alcohol use	281/293 (96)	82/87 (94)				
<i>PrEP persistence (has the participant taken PrEP over the past 30 days?)</i>						
Yes	222 (73)	72 (81)	0.63 [0.35-1.13]	0.12	0.65 [0.36, 1.19]	0.16
No	83 (27)	17 (19)				
<i>Time traveled to clinic and return (median, IQR)</i>	40 [30-60]	40 [30-60]	1.00 [0.99-1.01]	0.95	0.99 [0.99-1.01]	0.99

<i>minutes</i>						
<i>Cost to travel to clinic and return (median, IQR)</i>	1.29 [1.29-1.71]	1.29 [1.29-1.71]	1.12 [0.86-1.45]	0.40	1.11 [0.85-1.45]	0.44
<i>USD equivalent</i>						
<i>Contraceptive used in the past</i>						
Injection	252 (83)	60 (67)	2.30 [1.35-3.92]	0.002	2.48 [1.34, 4.57]	<0.01
Condom	172 (56)	45 (51)	1.26 [0.79-2.03]	0.33	1.59 [0.82, 3.07]	0.17
Implant	134 (44)	47 (53)	0.70 [0.44-1.12]	0.14	0.71 [0.44, 1.16]	0.17
Oral contraceptive	79 (26)	19 (21)	1.29 [0.73-2.27]	0.38	1.22 [0.69-2.17]	0.50
Female condom	4 (1)	4 (4)	0.28 [0.07-1.15]	0.08	0.27 [0.07-1.12]	0.07
Vaginal ring	1 (0.3)	1 (0.3)	0.29 [0.02-4.68]	0.38	0.27 [0.02-4.42]	0.36
<i>Oral PrEP likes</i>						
HIV prevention	298 (98)	87 (98)	0.98 [0.20-4.80]	0.98	0.95 [0.19-4.66]	0.95
No side effects	50 (16)	11 (12)	1.39 [0.69-2.80]	0.36	1.43 [0.71-2.90]	0.32
Ease of use	21 (7)	6 (7)	1.02 [0.40-2.62]	0.96	1.07 [0.41-2.75]	0.90
No interruption of sex	12 (4)	4 (4)	0.87 [0.27-2.77]	0.81	0.87 [0.27-2.80]	0.82
Easy to hide	7 (2)	3 (3)	0.67 [0.17-2.66]	0.57	0.63 [0.16-2.56]	0.52
Take it daily	4 (1)	4 (4)	0.28 [0.07-1.15]	0.08	0.30 [0.07-1.24]	0.10
Take it orally	4 (1)	3 (3)	0.38 [0.08-1.73]	0.21	0.38 [0.08-1.77]	0.22
Nothing	1 (0.3)	0 (0)	--	--	---	---
<i>Oral PrEP dislikes</i>						
Dislikes at least one thing about oral PrEP	158 (52)	35 (39)	1.66 [1.03-2.68]	0.04	1.72 [1.05, 2.80]	0.03
Side effects	81 (27)	18 (20)	1.43 [0.80-2.54]	0.23	1.43 [0.80, 2.55]	0.23
Daily use	75 (25)	13 (15)	1.91 [1.00-3.63]	0.05	1.92 [1.01, 3.67]	0.05
Take it orally	28 (9)	7 (8)	1.18 [0.50-2.81]	0.70	1.20 [0.50, 2.85]	0.69
Not discreet	7 (2)	2 (2)	1.02 [0.21-5.01]	0.98	1.09 [0.22, 5.46]	0.92
No STI protection	6 (2)	4 (4)	0.43 [0.12-1.55]	0.20	0.45 [0.12, 1.64]	0.23
<i>Preferred frequency of PrEP use</i>						
Ranked every month, 2-3 months, 6 months, or year #1	230 (75)	59 (66)	1.56 [0.94-2.60]	0.09	1.58 [0.94, 2.65]	0.08
Ranked before sex, after sex, or every day #1	75 (25)	30 (34)				
<i>Interested in community PrEP delivery</i>						
Yes	131 (43)	32 (36)	1.34 [0.82-2.19]	0.24	1.45 [0.85, 2.45]	0.17
No	174 (57)	57 (64)				

† Each individual model adjusted for maternal age, country
Bold p<0.10

Supplementary Table 1: Reasons behind preference of long-acting PrEP methods versus oral PrEP methods by pregnant and postpartum women with experience taking oral PrEP, South Africa and Kenya

If injectable PrEP was approved as safe for pregnant women to use, would you prefer to keep using oral PrEP or switch to the injection?	Overall (N=394)	South Africa (n=190)	Kenya (n=204)	p-value
Keep using oral PrEP	94 (24)	48 (25)	46 (23)	0.53
Switch to injectable PrEP	297 (75)	141 (74)	156 (76)	0.60
Unsure	3 (0.8)	1 (0.5)	2 (1)	0.53
<i>For those who selected injectable PrEP over oral PrEP: What characteristics about the injection make you interested in switching?</i>				
	Overall (n=297)	South Africa (n=141)	Kenya (n=156)	p-value
Longer duration/once every 8 weeks	188 (63)	123 (87)	65 (42)	<0.01
Not having to remember to take a pill every day	144 (48)	80 (57)	64 (41)	<0.01
Easy to keep private from my partner/others	83 (28)	7 (5)	76 (49)	<0.01
Administered by medical professional	40 (13)	9 (6)	31 (20)	<0.01
Not carrying pills	83 (28)	18 (13)	65 (42)	<0.01
Other (e.g., fewer potential side effects, comfort with contraceptive injection)	5 (2)	5 (4)	0 (0)	0.02
<i>For those who selected "Oral PrEP" or "Unsure": What characteristics about the injection make you not interested or unsure about switching?</i>				
	Overall (n=97)	South Africa (n=49)	Kenya (n=48)	p-value
Injection pain	71 (73)	37 (76)	34 (71)	0.60
Potential side effects	24 (25)	15 (31)	9 (19)	0.18
Not enough safety data (i.e. afraid of impact on me)	13 (13)	2 (4)	11 (23)	<0.01
Worry about impact on baby's health after delivery due to being on PrEP while breastfeeding	6 (6)	0 (0)	6 (13)	0.01
Worry about impact on having a healthy pregnancy due to PrEP	3 (3)	0 (0)	3 (6)	0.12
Once every 8 weeks	1 (1)	0 (0)	1 (2)	0.50
Other (e.g., needle fears, does not want more clinic, mistrust of contraceptive injection, used to oral PrEP)	5 (5)	5 (10)	0 (0)	0.03
If the vaginal ring was approved as safe for pregnant or breastfeeding women to use, would you prefer to keep using oral PrEP or switch to the vaginal ring?				
	Overall (N=394)	South Africa (n=190)	Kenya (n=204)	p-value
Keep using oral PrEP	344 (87)	165 (87)	179 (88)	0.79
Switch to vaginal ring	40 (10)	22 (12)	18 (9)	0.37
Unsure	10 (3)	3 (2)	7 (3)	0.20
<i>For those who selected vaginal ring over oral PrEP: What characteristics about the ring make you interested in switching?</i>				
	Overall (n=40)	South Africa (n=22)	Kenya (n=18)	p-value
Longer duration/once a month	17 (43)	14 (64)	3 (17)	<0.01
Not having to remember to take a pill every day	17 (43)	12 (55)	5 (28)	0.09
Easy to use	17 (43)	9 (41)	8 (44)	0.82
Not carrying pills	7 (18)	1 (5)	6 (33)	0.02
Unable to feel it	3 (8)	0 (0)	3 (17)	0.08
Easy to keep private from my partner/others	3 (8)	0 (0)	3 (17)	0.08
Fewer side effects	2 (5)	2 (9)	0 (0)	1
Other (familiarity with contraceptive ring/internal condom)	2 (5)	2 (9)	0 (0)	0.30
<i>For those who selected "Oral PrEP" or "Unsure": What characteristics about the ring make you not interested or unsure about switching?</i>				
	Overall (n=354)	South Africa (n=168)	Kenya (n=186)	p-value
Insertion into vagina	228 (64)	138 (82)	90 (48)	<0.01
Side effects	97 (27)	36 (21)	61 (33)	0.02
Not enough safety data (i.e. afraid of impact on me)	89 (25)	39 (23)	50 (27)	0.43
User or partner may feel it	51 (14)	13 (8)	38 (20)	<0.01
PrEP vaginal ring only reduces risk by 30%	37 (10)	24 (14)	13 (7)	0.03
Worry about impact on having a healthy pregnancy due to PrEP	25 (7)	5 (3)	20 (11)	<0.01

Worry about impact on baby's health after delivery due to being on PrEP while breastfeeding	28 (8)	6 (4)	22 (12)	<0.01
Once a month	15 (4)	3 (2)	12 (7)	0.03
Other (e.g. reduced risk/discomfort with incorrect usage, comfort with pills, fear that ring is scented, general discomfort/mistrust, ashamed)	14 (4)	11 (7)	3 (2)	0.02